Amgen 2019 financial report: the rise of 6 new products and the rise of biological similar drugs

On January 30, Amgen announced its performance in 2019, with a total revenue of 23.362 billion US dollars, a year-on-year decrease of 2%, which is mainly affected by the sharp decline of several core old products, such as neulasta (peifeigeting), sensipar / mimpara (sinakasai), Epogen (afayibotin), neupogen (feigeting) In 2018, FDA approved the listing of similar pefigeristine drugs from mylan / Bicon and coherus respectively The two drugs were sold at a price 33% lower than that of the original research, which caused great damage to neulasta Sensipar, which is used to treat secondary hyperparathyroidism, a common complication of patients with chronic kidney disease, fell off the patent cliff due to patent expiration and generic competition, and its sales directly shrank from the peak of $1774 million in 2018 to $551 million Sales volume of major drugs of Amgen in 2019 (US $100 million) However, Amgen is stepping into a new era of new product driven growth In recent years, the six approved innovative drugs kyprolis (multiple myeloma), repatha (hyperlipidemia), parsabiv (secondary hyperparathyroidism), blincyto (acute lymphocytic leukemia), aimovig (migraine), and evenity (osteoporosis) have gradually grown up, contributing to Amgen in total More than $3 billion in revenue In particular, the PCSK9 monoclonal antibody repatha for hyperlipidemia and the CGRP monoclonal antibody aimovig for migraine have achieved market leading positions Another area of Amgen's business is biologicals It can be said that Amgen is not only the victim of biological similar drugs, but also the beneficiary of biological similar drugs At present, three biological similar drugs have been approved and sold on the market, with a total sales revenue of 568 million US dollars in 2019 On December 13, 2019, avsola (infliximab) was also approved by FDA, which further expanded Amgen's bio similar drug territory Amgen also carried out two large-scale M & A transactions in 2019, including the acquisition of otezla, a psoriasis drug of Xinji, for us $13.4 billion in cash on August 27, 2019, clearing the way for the acquisition of BMS and Xinji The deal was completed on November 21, 2019, bringing Amgen $178 million in revenue in five weeks Amgen's revenue in 2020 is expected to be $25-25.6 billion, an increase of about $2 billion compared with 2019, a large part of which will come from otezla's contribution On November 1, 2019, Amgen and Baiji Shenzhou reached an in-depth cooperation to grant China's development and commercial rights to three mature drugs (xgeva, kyperolis and blincyto), as well as more than 20 new anti-tumor drugs under research, to Baiji Shenzhou, and acquired 20.5% shares of Baiji Shenzhou with us $2.7 billion The deal also marks that Amgen's expansion of the Chinese market mainly depends on its partners rather than playing in the next game.